Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

UnitedHealth Shares Climb, Reinforcing Strong Market Position Amid Healthcare Shifts

UnitedHealth Group shares climb, buoyed by its broad health‑insurance portfolio and steady shareholder activity, showing resilience amid market volatility and evolving ACA plans.

Dr. Sarah Winters

26/09/2026, 20:32

2 minutes to read

How Eisai Co. is Leading Autoimmune Treatment Innovation in 2026

Discover how Eisai Co., Ltd. leads in autoimmune treatment with innovative biologics, biosimilars, and precision medicine—boosting efficacy, safety, and patient access worldwide.

Dr. Sarah Winters

26/09/2026, 09:27

3 minutes to read

Fresenius Short‑Position Disclosure: No Impact on Products or Patient Care

Fresenius SE & Co. KGaA’s 0.5% short‑position filing is a routine regulatory update—no impact on products, pricing or patient care.

Dr. Sarah Winters

26/09/2026, 00:14

3 minutes to read

How Natera’s Genomics Tech Keeps Investors and Healthcare Ahead in Market Volatility

Explore how Natera’s non‑invasive prenatal & liquid biopsy tech keeps biotech stocks steady amid geopolitical turbulence, boosting patient care and investor confidence.

Dr. Sarah Winters

25/09/2026, 05:34

3 minutes to read

Stable Mid‑Cap: Sandoz Group’s Consistent Swiss Market Performance and Dividend Reliability

Discover why Sandoz Group AG is a steady mid‑cap in the Swiss market, offering modest growth, reliable dividends, and solid pharma valuation.

Dr. Sarah Winters

24/09/2026, 22:00

2 minutes to read

Fresenius SE & Co. KGaA Shares Rise 0.5% as DAX Gains; Market Impact Explained

Fresenius SE & Co. KGaA’s shares rose modestly on September 8, 2026, echoing a slight DAX uptick. The article examines why the German healthcare firm remains a top DAX performer, its market cap standing, and investor sentiment amid broader index vol…

Dr. Sarah Winters

24/09/2026, 14:47

2 minutes to read

Siemens Healthineers Shares Dip as Market Volatility Surges, Yet Diagnostics Tech Leads

Siemens Healthineers shares dip 1.3% as markets stay cautious, yet its AI‑driven analyzers, multiplex immunoassays, and point‑of‑care tech keep the firm ahead in rapid, accurate diagnostics.

Dr. Sarah Winters

24/09/2026, 00:27

3 minutes to read

Novo Nordisk Investor Briefing: $18M UNICEF Partnership & Zenagamtide Strategy Reveal

Explore Novo Nordisk’s dual strategy: investor‑briefing insights on Zenagamtide’s safety, and an $18 M UNICEF partnership targeting 80 M children’s obesity prevention.

Dr. Sarah Winters

23/09/2026, 19:14

4 minutes to read

EssilorLuxottica Faces Smart‑Glasses Probe, Share Buyback & Tightening Margins Ahead of Earnings

EssilorLuxottica faces a privacy probe into its smart‑glasses line, while traditional eyewear margins shrink—stock buyers weigh the implications.

Dr. Sarah Winters

23/09/2026, 09:41

3 minutes to read

ResMed Accelerates Connected Health Growth with Data‑Driven Sleep Care

ResMed’s data‑driven connected devices boost sleep‑disorder care, driving sales, regulatory approval, and supply‑chain resilience while improving patient adherence and cost‑efficiency.

Dr. Sarah Winters

23/09/2026, 04:38

3 minutes to read

Newer articles